- Home
- DXLG vs TELA Comparison
DXLG vs TELA Comparison
Compare DXLG & TELA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DXLG | TELA |
|---|---|---|
| Founded | 1976 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.2M | 37.5M |
| IPO Year | 1994 | 2019 |
Fundamental Metrics
Financial Performance| Metric | DXLG | TELA |
|---|---|---|
| Price | $0.50 | $0.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $2.50 | ★ $3.31 |
| AVG Volume (30 Days) | ★ 100.8K | 58.2K |
| Earning Date | 03-19-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 34.80 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $467,015,000.00 | $69,300,000.00 |
| Revenue This Year | N/A | $18.41 |
| Revenue Next Year | $3.24 | $15.20 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 18.56 |
| 52 Week Low | $0.47 | $0.67 |
| 52 Week High | $1.88 | $2.19 |
Technical Indicators
Market Signals| Indicator | DXLG | TELA |
|---|---|---|
| Relative Strength Index (RSI) | 41.16 | 42.46 |
| Support Level | $0.49 | $0.67 |
| Resistance Level | $0.57 | $1.22 |
| Average True Range (ATR) | 0.07 | 0.09 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 12.81 | 22.72 |
Price Performance
Historical ComparisonAbout DXLG Destination XL Group Inc.
Destination XL Group Inc is a retailer of branded and Tall men's clothing and shoes in the United States. It also sells products across the world. The company sells its products under the trade names Destination XL, DXL, DXL Men's Apparel, DXL outlets, Casual Male XL, and Casual Male XL outlets. The company has two principal operating segments: Store, and Direct business.
About TELA TELA Bio Inc.
TELA Bio Inc a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.